文献速递淋巴瘤

套细胞淋巴瘤治疗策略的演变:进展与未来方向

Evolving therapeutic strategies in mantle cell lymphoma: advancements and future directions.
PubMed 文献 · Leukemia · 2026-04-15

套细胞淋巴瘤(MCL)是一种生物学和临床异质性的B细胞恶性肿瘤,历史预后较差。近期靶向治疗、无化疗方案和细胞疗法的整合显著扩展了治疗选择。本文综述了MCL当前和新兴的治疗方法,强调生物制剂、策略性组合和以患者为中心的方法如何推动MCL治疗进入新阶段。

要点

  • 一线治疗已纳入BTK抑制剂联合化疗及无化疗方案。
  • 复发/难治患者尤其BTKi经治者可用CAR-T和三代BTKi如pirtobrutinib。
  • 双特异性抗体等新药在研,高危患者持久缓解仍是挑战。

核心结论

  • 靶向治疗、无化疗方案和细胞疗法的整合显著扩展了MCL治疗选择,但高危患者持久缓解仍是主要挑战。

研究设计与样本

  • 综述,总结MCL当前和新兴治疗策略。

主要发现

  • 一线治疗纳入BTK抑制剂联合化疗及无化疗方案。
  • 复发/难治尤其BTKi经治患者,CAR-T和三代BTKi如pirtobrutinib提供高效选择。
  • 双特异性抗体等多种新药正在研究中。

临床怎么用

  • 一线可考虑含BTK抑制剂联合化疗或无化疗方案。
  • 复发/难治尤其BTKi暴露后可选CAR-T或三代BTKi如pirtobrutinib。

局限性

  • 综述性文章,未报告原始研究数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mantle cell lymphoma (MCL) is a biologically and clinically heterogeneous B-cell malignancy with a historically poor prognosis. Recent advances have substantially expanded treatment options, particularly through the integration of targeted therapies, chemotherapy-free regimens, and cellular approaches. Frontline treatment now incorporates Bruton's tyrosine kinase inhibitors (BTKi) in combination with chemotherapy and in chemotherapy-free regimens. For patients with relapsed or refractory disease, particularly those previously exposed to BTKi, chimeric antigen receptor T-cell (CAR T) therapies and third-generation BTKi like pirtobrutinib provide highly effective options while several novel agents, including bispecific antibodies (bsAbs), are under investigation. Nevertheless, achieving long-lasting remissions is still a major challenge, especially among high-risk patients. Future directions include optimizing sequencing, refining rational combination therapies, expanding the application of bsAbs, and integrating small molecules and novel immunoconjugates to enhance therapeutic efficacy and long-term outcomes. This review provides an overview of the current and emerging therapies for MCL, highlighting how the integration of biological agents, strategic combinations, and patient-centered approaches are driving the next phase of MCL treatment.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Tavarozzi R, Maher N, Catania G, et al. Evolving therapeutic strategies in mantle cell lymphoma: advancements and future directions. Leukemia. 2026. PMID: 41986622. doi:10.1038/s41375-026-02942-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。